

# ENLIGHT Meeting

## Novel Imaging Systems.....

CERN, 2nd September

Manjit Dosanjh  
ENLIGHT Coordinator

FP7 Cooperation Work Programme: Health



### ***1.2. Detection, diagnosis and monitoring***

Topics for 3rd call, one stage submission and evaluation; deadline November 2008	Funding scheme
HEALTH-2009-1.2-1: Development of tools for sensitive and specific detection of proteins and their interactions for diagnostic, prognostic and monitoring purposes	Small or medium scale focused research project
HEALTH-2009-1.2-2: Design of methods suited to identify epigenetic factors and their use in the genetic diagnosis of relevant disorders	Small or medium scale focused research projects with maximum EC contribution of EUR 3 000 000
HEALTH-2009-1.2-3: Novel MR-compatible PET detectors for simultaneous PET/MRI imaging	Large scale integrating project with maximum EC contribution of EUR 12 000 000 / project
HEALTH-2009-1.2-4: Novel imaging systems for in vivo monitoring and quality control during tumour ion beam therapy	Small or medium scale focused research project
HEALTH-2009-1.2-5: Activatable or smart in vivo imaging agents reporting on physico-chemical or molecular changes relevant to the diagnosis and/or monitoring of diseases	Small or medium scale focused research project
HEALTH-2009-1.2-6: Evaluation of the potential health impact of Diagnostic Imaging agents doses	Coordination and Support Action (Support Action) with maximum EC contribution of EUR 500 000 / project

**HEALTH- 2009-1.2-4: Novel imaging systems for in vivo monitoring and quality control during tumour ion beam therapy.**



**Single stage application.**

**Collaborative project (small or medium-scale focused research project)**

The focus should be to develop **novel** imaging instruments, methods and tools for monitoring, in vivo and **preferably** in real time, the 3-dimensional distribution of the radiation dose effectively delivered within the patient during ion beam therapy of cancer. The ions **should be protons or heavier ions**. The system **should typically** be able to quantify the radiation dose delivered, to determine the agreement between the planned target volume and the actually irradiated volume, and for decreasing localisation uncertainties between planned and effective positions (e.g. of tissues or organs), and between planned and effective dose distribution during irradiation. It **should** aim at improving quality assurance, increasing target site (tumour) to normal tissue dose ratio and better sparing normal tissue.

2.9.2008

Manjit Dosanjh



**Call statistics**

Call publication:	3 <sup>rd</sup> September
Deadline for submission:	3 <sup>rd</sup> December @ 17.00 hrs
Submission:	electronic, single stage

Maximum funding:	€ 6 million
Projects to be funded under 1.2-4:	1
Typical consortium size:	12 - 15 partners

2.9.2008

Manjit Dosanjh

## Objectives of the meeting

- Identification of the WPs and their approximate contents
- Provisional list of the participating Institutes in each WP
- Choice of at least one co-convener per WP
- Decisions about the follow-up procedure to be followed by the co-conveners and the Steering Committee
- Strategy for preparing of final document for submitting on the 3rd of December